相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong et al.
CANCER DISCOVERY (2020)
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Angeles Alvarez Secord et al.
CLINICAL CANCER RESEARCH (2020)
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martinez Changa et al.
LANCET ONCOLOGY (2019)
The multiple functions and mechanisms of osteopontin
Mehmet Arif Icer et al.
CLINICAL BIOCHEMISTRY (2018)
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Yingmiao Liu et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities
Vahid Farrokhi et al.
SCIENTIFIC REPORTS (2018)
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
Martin H. Voss et al.
BRITISH JOURNAL OF CANCER (2016)
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Ace J. Hatch et al.
CANCER MEDICINE (2016)
Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
Brian Shuch et al.
EUROPEAN UROLOGY (2015)
Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Yingmiao Liu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Andrew B. Nixon et al.
CLINICAL CANCER RESEARCH (2013)
Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Hai T. Tran et al.
LANCET ONCOLOGY (2012)
Therapy for Non-Clear Cell Histologies in Renal Cancer
Rhonda L. Bitting et al.
CURRENT CLINICAL PHARMACOLOGY (2011)
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
Janice P. Dutcher et al.
MEDICAL ONCOLOGY (2009)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
